Indication
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
5 clinical trials
8 products
2 drugs
Product
INCA00186Product
RetifanlimabProduct
INCB106385Clinical trial
A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-06-30
Clinical trial
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 2 STUDY OF PALBOCICLIB PLUS CETUXIMAB VERSUS CETUXIMAB FOR THE TREATMENT OF HUMAN PAPILLOMAVIRUS-NEGATIVE, CETUXIMAB-NAÏVE PATIENTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AFTER FAILURE OF ONE PRIOR PLATINUM-CONTAINING CHEMOTHERAPY REGIMENStatus: Completed, Estimated PCD: 2018-07-19
Product
palbociclibProduct
CetuximabProduct
PlaceboClinical trial
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-07
Product
XB002Drug
T-VECClinical trial
Chemo-embolization for Head and Neck CancerStatus: Not yet recruiting, Estimated PCD: 2028-01-01
Drug
CisplatinClinical trial
A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and NeckStatus: Completed, Estimated PCD: 2023-04-14
Product
Nivolumab + Pemetrexed